These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27673381)

  • 1. Translating nutritional immunology into drug development for inflammatory bowel disease.
    Leber A; Hontecillas R; Tubau-Juni N; Bassaganya-Riera J
    Curr Opin Gastroenterol; 2016 Nov; 32(6):443-449. PubMed ID: 27673381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.
    Holleran G; Lopetuso L; Petito V; Graziani C; Ianiro G; McNamara D; Gasbarrini A; Scaldaferri F
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiota in the pathogenesis of inflammatory bowel disease.
    Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A
    Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal interaction of diet and microbiome in inflammatory bowel diseases.
    Schaubeck M; Haller D
    Curr Opin Gastroenterol; 2015 Nov; 31(6):464-70. PubMed ID: 26406564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current stage in inflammatory bowel disease: What is next?
    Gómez-Gómez GJ; Masedo Á; Yela C; Martínez-Montiel Mdel P; Casís B
    World J Gastroenterol; 2015 Oct; 21(40):11282-303. PubMed ID: 26525013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut biofilm forming bacteria in inflammatory bowel disease.
    Srivastava A; Gupta J; Kumar S; Kumar A
    Microb Pathog; 2017 Nov; 112():5-14. PubMed ID: 28942174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.
    de Souza HSP; Fiocchi C; Iliopoulos D
    Nat Rev Gastroenterol Hepatol; 2017 Dec; 14(12):739-749. PubMed ID: 28831186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease.
    Farzaei MH; Bahramsoltani R; Abdolghaffari AH; Sodagari HR; Esfahani SA; Rezaei N
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):745-58. PubMed ID: 26799847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse models of inflammatory bowel disease for investigating mucosal immunity in the intestine.
    Bamias G; Arseneau KO; Cominelli F
    Curr Opin Gastroenterol; 2017 Nov; 33(6):411-416. PubMed ID: 28901966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of nutraceutical compounds in inflammatory bowel disease.
    Larussa T; Imeneo M; Luzza F
    World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective therapeutic targets and recent advancements in the treatment of inflammatory bowel disease.
    Sinha A; Roy S
    Immunopharmacol Immunotoxicol; 2024 Aug; 46(4):550-563. PubMed ID: 39013809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and inflammatory bowel disease: so far so gut!
    Holleran G; Lopetuso LR; Ianiro G; Pecere S; Pizzoferrato M; Petito V; Graziani C; McNAMARA D; Gasbarrini A; Scaldaferri F
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):373-384. PubMed ID: 28293937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating inflammatory bowel disease research into clinical medicine.
    Neurath MF; Finotto S
    Immunity; 2009 Sep; 31(3):357-61. PubMed ID: 19766078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the management of inflammatory bowel disease.
    Grimpen F; Pavli P
    Intern Med J; 2010 Apr; 40(4):258-64. PubMed ID: 20059603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional components regulate the gut immune system and its association with intestinal immune disease development.
    Lamichhane A; Kiyono H; Kunisawa J
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():18-24. PubMed ID: 24251698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
    Babickova J; Gardlik R
    World J Gastroenterol; 2015 Oct; 21(40):11321-30. PubMed ID: 26525290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectively targeting the gut in inflammatory bowel disease: Session four summary.
    Begun J
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():25. PubMed ID: 30187550
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune aspects of the pathogenesis of inflammatory bowel disease.
    Hisamatsu T; Kanai T; Mikami Y; Yoneno K; Matsuoka K; Hibi T
    Pharmacol Ther; 2013 Mar; 137(3):283-97. PubMed ID: 23103332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.